| Date | Title | Description |
| 26.09.2024 | Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say | Future of HealthRegulatory Oversight
Commercial Strategy
Regulatory
Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say
By Kashish Tandon and Christy SanthoshSeptember 26, 20243:40 PM UTCUpdated ago... |
| 14.05.2024 | ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages bluebird bio Inc. Investors to Secure Counsel Before Important May 28 Deadline in Securities Class Action - BLUE | New York, May 14, 2024 /PRNewswire/ --
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of bluebird bio, Inc. (NASDAQ: BLUE) between April 24, 2023 and December 8, 2023, both dates inclusive (the &q... |
| 07.05.2024 | ROSEN, A LEADING NATIONAL FIRM, Encourages bluebird bio Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BLUE | NEW YORK, May 7, 2024 /PRNewswire/ --
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of bluebird bio, Inc. (NASDAQ: BLUE) between April 24, 2023 and December 8, 2023, both dates inclusive (the &qu... |
| 20.03.2024 | Startup Lands $150M for Delicate Dance Between Cancer Cells & Immune Cells | Cancer immunotherapy comes in several forms, and one area of growing research interest is a type of drug called a T cell engager. These drugs bind to a cancer cell and a T cell simultaneously, bringing both of them together to spark a thera... |
| 08.03.2024 | CAR T-Cell Therapy Market Set for Healthy Growth after COVID19 Pandemic Top Players Industry Trends and Forecast 2032 | CHICAGO, UNITED STATES, March 8, 2024 /EINPresswire.com/ -- Astute Analytica, a leading provider of market research and analysis, released its highly anticipated Market Analysis Report on the Global 𝐂𝐀𝐑 𝐓-𝐂𝐞𝐥𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐌𝐚𝐫𝐤𝐞𝐭. This comprehen... |
| 08.09.2021 | bluebird bio : Secures $75 Million in Private Placement Equity Financing | bluebird bio, Inc. (NASDAQ: BLUE) announced today that it has entered into an agreement for a $75 million private placement of common stock and common stock equivalents with a healthcare investment fund selected as part of a competitive pro... |
| 07.06.2021 | BLUEBIRD BIO, INC.
Bluebird bio : Announces the Lifting of FDA Clinical Hold for Sickle Cell Disease and β-Thalassemia Studies (Form 8-K) | bluebird bio Announces the Lifting of FDA Clinical Hold for Sickle Cell Disease and β-Thalassemia Studies
CAMBRIDGE, Mass. - (BUSINESS WIRE) - June 7, 2021- bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.S. Food and Drug Admin... |
| 26.02.2021 | bluebird bio to Present at Cowen Health Care Conference | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 26, 2021--
bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the Cowen 41 st Annual Health Care Conference, Wednesday, March 3, at 2:40 p.m. ET.
... |
| 24.02.2021 | The New England Journal of Medicine Publishes Results from Pivotal Phase 2 KarMMa Study of Idecabtagene Vicleucel (Ide-cel, bb2121), an Investigational BCMA-Directed CAR T Cell Therapy | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 24, 2021--
Results from the pivotal Phase 2 KarMMa study evaluating the efficacy and safety of bluebird bio, Inc. (Nasdaq: BLUE) and Bristol Myers Squibb ’s (NYSE: BMY) investigational B-cell maturatio... |
| 05.06.2018 | We just got a lot of updates on the state of cancer treatments - here are the winners and losers | ASCO
Advertisement
Over the weekend at the American Society of Clinical Oncologists meeting, a lot of updates and new data were presented.
It sent stocks all over the place Monday with the biggest movers being Bristol-Myers Squibb, Nektar, ... |
| 09.04.2018 | Novartis just handed out a $8.7 billion endorsement for new therapies that are changing how we treat genetic diseases | Reuters
Novartis CEO Vas Narasimhan
Advertisement
Novartis is acquiring gene therapy company AveXis for $8.7 billion.
AveXis is working on a gene therapy for spinal muscular atrophy, a rare genetic condition that affects muscle movement in ... |
| 12.12.2017 | bluebird bio and TC BioPharm Announce Strategic Collaboration to Research and Develop Gamma Delta CAR T Cell Product Candidates for Cancer Immunotherapy | – Deal combines TC BioPharm’s leading gamma delta T Cell capabilities with bluebird’s proven expertise in all stages of CAR T and gene therapy product development to discover and develop next-generation liquid and solid tumor product candid... |
| 12.12.2017 | bluebird bio and TC BioPharm Announce Strategic Collaboration to Research and Develop Gamma Delta CAR T Cell Product Candidates for Cancer Immunotherapy | – Deal combines TC BioPharm’s leading gamma delta T Cell capabilities with bluebird’s proven expertise in all stages of CAR T and gene therapy product development to discover and develop next-generation liquid and solid tumor product candid... |
| 31.10.2016 | Third Rock Ventures closes $616 million healthcare fund | Fund IV has not yet begun investing, according to a company representative, but the firm has established a strong track record with its first three funds. In less than 10 years, Third Rock has invested in 40 companies, advancing 40 clinical... |
| 20.07.2016 | Former Bluebird Bio (BLUE) CSO Takes the Reins at Oncorus; Startup Launches with $57 Million Series A | - |
| 15.01.2015 | Just a cool #JPM15 Bluebird Bio slide that shows its impressive scope | The company’s stock has just killed it in the past year – from $BLUE trading around $17 per share a year ago to hitting highs above $100 this year.
Biopharma Dive wrote of the #JPM15 presentation:
It’s one of the hottest biotechs in the wor... |
| 09.01.2014 | bluebird bio Appoints Dr James Mandell to its Board of Directors | CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 9, 2014– bluebird bio, a clinical-stage biotechnology company focused on transforming the lives of patients with severe genetic and orphan diseases using gene therapy, announced today that James Mandell... |
| 28.08.2013 | 11 health companies make the World Economic Group tech pioneer list | Nearly one-third of the 36 emerging technology pioneers chosen by the World Economic Forum this year have implications for the life sciences and health IT space. They represent robotics, noninvasive prenatal testing, using edible identifier... |
| 27.07.2012 | Fundraising: Gene therapy firm targeting sickle cell anemia raises $60M | Product: Gene therapy to target sickle cell anemia, beta-thalassemia and childhood cerebral adrenoleukodystrophy
Money raised: $60 million in series D; at least $76 million in previous rounds based on press releases and U.S. Securities and ... |
| 25.07.2012 | bluebird bio Closes $60M Series D Funding | bluebird bio, a Cambridge, Mass., and Paris-based developer of gene therapies for severe genetic disorders, has closed a $60m Series D funding.
Backers include new investors Deerfield Partners, RA Capital, and Ramius Capital Group, as well ... |
| 25.07.2012 | bluebird bio Secures $60 Million in Oversubscribed Financing | Proceeds will Further Strengthen bluebird’s Proprietary Gene Therapy Platform and Advance Multiple Clinical Programs in Severe Genetic Disorders, Including a Global ALD Phase 2/3 Study
CAMBRIDGE, Mass., July 25, 2012 — bluebird bio, a lead... |
| 25.07.2012 | bluebird bio Sings to $60 million Series D |
CAMBRIDGE, MA, Leader in the development of innovative gene therapies for severe genetic disorders, today announced the successful completion of a $60 million Series D round.
>> Click here for more funding data on bluebird bio
>... |
| 20.04.2011 | bluebird bio Raises $30M | bluebird bio, a Cambridge, Mass. and Paris, France-based developer of innovative gene therapies for severe genetic disorders, raised an additional $30m in financing.
Investors include new shareholder ARCH Venture Partners, and existing back... |
| 20.04.2011 | bluebird bio Secures Additional $30 Million in Financing | ARCH Venture Partners Joins Investor Team
New Financing Will Further Advance the Beta-Thalassemia, Sickle Cell Anemia
and ALD Clinical Programs While Accelerating the Product Platform Build
CAMBRIDGE, Mass., April 20, 2011 – bluebird bio... |
| 22.03.2011 | Bovie Medical names new president, shuffles board | Personnel moves | Bovie Medical Corp. (NYSE:BVX) announced a flurry of personnel moves in its corner office and board room.
The company said current president and CEO Andrew Makrides will relinquish his title of president but keep his position as chief execu... |
| 15.09.2010 | Bluebird Bio, Third Rock & Genzyme’s Gene Therapy Bet, Shows Promise for Blood Disorder | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
Genzyme and Third Rock Ventures bet $35 million six months ago on a Cambridge, MA-based gene therapy company. Despite all the ups and downs with gene therapy over the years, n... |
| - | Third Rock Ventures closes $616 million healthcare fund | Third Rock Ventures announced Monday that it had closed its fourth fund — it’s largest, Third Rock Ventures IV — for an oversubscribed $616 million.
The Boston, Massachusetts-based firm now has a total of $1.9 billion in assets under manage... |
| - | Just a cool #JPM15 Bluebird Bio slide that shows its impressive scope | Bluebird Bio‘s work has been at the epicenter of gene therapy, working on a litany of fields that intersect with the work of the industry’s top firms. This slide from its J.P. Morgan presentation this week illustrates that quite nicely:
Awe... |
| - | bluebird bio Provides Updated Findings from Reported Case of Acute Myeloid Leukemia (AML) in LentiGlobin for Sickle Cell Disease (SCD) Gene Therapy Program | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 10, 2021--
bluebird bio, Inc. (Nasdaq: BLUE) announced today that based on the analyses completed to date, it is very unlikely the Suspected Unexpected Serious Adverse Reaction (SUSAR) of acute myeloid... |
| - | An unmet medical need in treating rare genetic blood disorders | The hemoglobinopathies are a group of inherited blood disorders caused by mutations affecting the globin genes and include sickle cell disease and the alpha (α-) and beta (β-) thalassemias.[1] The β-hemoglobinopathies, genetic diseases caus... |
| - | bluebird bio Presents Long-Term Data for elivaldogene autotemcel (eli-cel, Lenti-D™) Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 15, 2021--
bluebird bio, Inc. (Nasdaq: BLUE) announced new data from the clinical development program for its investigational elivaldogene autotemcel (eli-cel, Lenti-D™) gene therapy in patients with c... |
| - | Bluebird Bio gene therapy wins first FDA approval for rare blood disorder | A Bluebird Bio gene therapy that treats the rare blood disorder beta thalassemia is now approved by the FDA, providing the option for a one-time treatment that could eliminate the need for regular blood transfusions patients undergo as the ... |
| - | 11 health companies make the World Economic Group tech pioneer list | Nearly one-third of the 36 emerging technology pioneers chosen by the World Economic Forum this year have implications for the life sciences and health IT space. They represent robotics, noninvasive prenatal testing, using edible identifier... |
| - | Fundraising: Gene therapy firm targeting sickle cell anemia raises $60M | Company name: bluebird bio.
Industry: Biotechnology.
Location: Cambridge, Massachusetts.
Product: Gene therapy to target sickle cell anemia, beta-thalassemia and childhood cerebral adrenoleukodystrophy
Money raised: $60 million in series D;... |
| - | bluebird bio Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Operational Progress | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 23, 2021--
bluebird bio, Inc. (NASDAQ:BLUE) today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2020 and shared recent operational progress.... |
